Evan Jones Biography and Net Worth

Director of Veracyte

Evan Jones began serving as a member of Veracyte’s board of directors in 2008. Mr. Jones has achieved a distinguished career leading and investing in pioneering life sciences companies. He has served as Managing Member of jVen Capital, LLC, a life sciences investment company, since 2007. He previously served as Chief Executive Officer of OpGen Inc., a publicly held genetic analysis company, from 2013 to March 2020, and as a director from 2009 to 2020. Mr. Jones co-founded Digene Corporation, a publicly traded molecular diagnostics company focused on women’s health, serving as Chairman of the Board from 1995 until its acquisition in 2007 and as Chief Executive Officer from 1990 to 2006. He is a member of the board of directors for Protagene GmbH, a leading provider of analytical services for biologicals and cell and gene therapy development. He previously served as a member of the board of directors of Foundation Medicine, Inc., Fluidigm Corporation and CAS Medical Systems, Inc. Mr. Jones received a B.A. in Biotechnology from the University of Colorado and an M.B.A. from The Wharton School at the University of Pennsylvania.

What is Evan Fa Jones' net worth?: The estimated net worth of Evan Fa Jones is at least $1.18 million as of September 19th, 2024. Mr. Jones owns 34,343 shares of Veracyte stock worth more than $1,178,308 as of November 2nd. This net worth evaluation does not reflect any other assets that Mr. Jones may own. Learn More about Evan Fa Jones' net worth.
How do I contact Evan Fa Jones?: The corporate mailing address for Mr. Jones and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Evan Fa Jones' contact information.
Has Evan Fa Jones been buying or selling shares of Veracyte?: Evan Fa Jones has not been actively trading shares of Veracyte during the last ninety days. Most recently, Evan/ Fa Jones sold 5,173 shares of the business's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $35.23, for a transaction totalling $182,244.79. Following the completion of the sale, the director now directly owns 34,343 shares of the company's stock, valued at $1,209,903.89. Learn More on Evan Fa Jones' trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 63,827 shares worth more than $1,779,423.17. The most recent insider tranaction occured on September, 19th when Director Evan/ Fa Jones sold 5,173 shares worth more than $182,244.79. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 9/19/2024.

Evan Fa Jones Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/19/2024	Sell	5,173	$35.23	$182,244.79	34,343
8/13/2024	Sell	20,457	$32.20	$658,715.40	34,343
8/9/2024	Sell	1,032	$30.03	$30,990.96	46,413
12/13/2022	Sell	1,667	$30.71	$51,193.57	50,784
11/11/2022	Sell	6,000	$30.23	$181,380.00	52,451
8/3/2020	Sell	20,000	$35.16	$703,200.00	25,000
7/31/2020	Sell	20,000	$35.67	$713,400.00	25,000
7/15/2020	Sell	30,000	$28.93	$867,900.00	25,000
1/16/2020	Sell	14,049	$30.11	$423,015.39	25,000
1/14/2020	Sell	5,000	$28.50	$142,500.00	25,000
12/17/2019	Sell	15,000	$29.26	$438,900.00	25,000
8/28/2019	Sell	10,000	$26.11	$261,100.00	25,000
8/9/2019	Sell	15,000	$26.38	$395,700.00	25,000
8/28/2017	Sell	22,500	$7.81	$175,725.00
8/24/2017	Sell	40,000	$7.88	$315,200.00
8/23/2017	Sell	20,000	$7.92	$158,400.00
11/25/2015	Sell	7,896	$7.23	$57,088.08
11/24/2015	Sell	7,104	$7.20	$51,148.80
9/9/2014	Sell	27,304	$12.60	$344,030.40
6/12/2014	Sell	16,650	$15.07	$250,915.50
6/9/2014	Sell	22,870	$14.57	$333,215.90
6/5/2014	Sell	28,248	$14.33	$404,793.84
5/30/2014	Sell	23,882	$15.33	$366,111.06

Evan Fa Jones Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Today's Range

Now: $34.31

$33.61

$34.36

50 Day Range

MA: $32.83

$28.57

$35.25

2 Week Range

Now: $34.31

$18.61

$35.51

Volume

553,888 shs

Average Volume

632,445 shs

Market Capitalization

$2.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Banking failure dead ahead

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.